Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients

doi:10.12998/wjcc.v9.i36.11156

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 36

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3944)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

235

WORD

128

HTML

2526

Tables (1-4)

195

Sum=3084

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

269

Download

591

Sum=860

Dec 26, 2021 (publication date) through Aug 26, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Clin Cases. Dec 26, 2021; 9(36): 11156-11164
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11156

Table 1 Clinical and metabolic characteristics of the three groups

Characteristics	NC	T2DM	DPN
n	39	49	47
Gender (M/F)	20/19	23/26	24/23
Age (yr)	52.31 ± 1.93	54.20 ± 1.58	58.87 ± 1.40
BMI (kg/m²)	24.04 ± 0.45	27.91 ± 0.55^a	26.67 ± 0.52^a
Diabetes duration (yr)	-	1.00 (0.20-4.50)	10.00 (4.00-15.00)^c
SBP (mmHg)	128 (119-133)	131 (118-146)^a	141 (126-153)^a
DBP (mmHg)	75.97 ± 0.89	85.96 ± 1.48^a	86.79 ± 1.73^a
FPG (mmoL/L)	5.31 (4.92-5.79)	9.02 (7.30-10.61)^a	8.09 (6.77-9.89)^a
HbA_1c (%)	5.50 ± 0.05	8.92 ± 0.29^a	8.06 ± 0.26^a
FCP (ng/mL)	1.65 (1.18-2.19)	1.24 (1.00-2.02)	1.31 (0.85-2.16)
FINS (uIU/mL)	6.87 (4.35-9.60)	5.85 (3.25-10.30)	6.84 (3.90-9.97)
HOMA-IR	1.49 (1.00-2.42)	2.42 (1.26-4.18)^a	2.59 (1.23-4.50)^a
TG (mmoL/L)	0.90 (0.62-1.24)	1.93 (1.32-3.87)^a	1.89 (1.12-2.75)^a
LDL (mmoL/L)	3.02 ± 0.13	3.07 ± 0.13	3.08 ± 0.17
HDL (mmoL/L)	1.36 ± 0.06	1.13 ± 0.04^a	1.25 ± 0.05^a
SCr (umoL/L)	50.33 ± 2.84	64.7 ± 2.01^a	63.56 ± 1.96^a
BUN (mmoL/L)	5.27 ± 0.25	3.41 ± 0.21	4.84 ± 0.15^c
UA (mmoL/L)	300.90 ± 10.80	309.79 ± 10.48	282.58 ± 11.74
eGFR (mL/min/1.73m²)	154.90 (122.90-214.60)	116.30 (101.40-140.30)^a	114.00 (98.16-130.00)^a
Sestrin2 (ng/mL)	9.10 (5.41,13.53)	14.58 (7.93-26.62)^a	9.86 (6.72-21.71)^c

^aP < 0.05 vs normal control group.

^cP < 0.05 vs type 2 diabetes mellitus group.

M: Male; F: Female; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting plasma glucose; HbA_1c: Glycosylated hemoglobin A1_c; FCP: Fasting C peptide; FINS: Fasting insulin; HOMA-IR: Homeostasis model assessment of insulin resistance; TG: Triglyceride; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; Scr: Serum creatinine; BUN: Blood urea nitrogen; UA: Uric acid; eGFR: Estimated glomerular ﬁltration rate; NC: Normal control; T2DM: Type 2 diabetes mellitus; DPN: Diabetic peripheral neuropathy.

Citation: Mao EW, Cheng XB, Li WC, Kan CX, Huang N, Wang HS, Hou NN, Sun XD. Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients. World J Clin Cases 2021; 9(36): 11156-11164
URL: https://www.wjgnet.com/2307-8960/full/v9/i36/11156.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i36.11156